Approval Application for ANCA-Associated Vasculitis Drug Amended by Developer
According to a story from ANCA Vasculitis News, the biopharmaceutical company ChemoCentryx has recently made an amendment to its approval application for its investigational therapy. This therapy, called avacopan, is…